90. Retinitis pigmentosa
103 clinical trials,   158 drugs   (DrugBank: 42 drugs),   52 drug target genes,   107 drug target pathways

Searched query = "Retinitis pigmentosa", "Rod dystrophy", "Rod-Cone Dystrophy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01530659
(ClinicalTrials.gov)
January 201219/1/2012Retinal Imaging of Subjects Implanted With Ciliary Neurotrophic Factor (CNTF)-Releasing Encapsulated Cell Implant for Early-stage Retinitis PigmentosaPhotoreceptor Structure in A Phase 2 Study of Encapsulated Human NTC-201 Cell Implants Releasing Ciliary Neurotrophic Factor (CNTF) for Participants With Retinitis Pigmentosa Using Rates of Change in Cone Spacing and DensityRetinitis Pigmentosa;Usher Syndrome Type 2;Usher Syndrome Type 3Drug: NT-501;Procedure: ShamNeurotech PharmaceuticalsUniversity of California, San Francisco;FDA Office of Orphan Products DevelopmentUnknown status18 Years55 YearsAll30Phase 2United States
2NCT00447993
(ClinicalTrials.gov)
January 20079/3/2007A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis PigmentosaA Phase II/III Study of Encapsulated Human NTC-201 Cell Implants Releasing Ciliary Neurotrophic Factor (CNTF) for Participants With Retinitis Pigmentosa Using Visual Acuity as the Primary OutcomeRetinitis PigmentosaDrug: NT-501Neurotech PharmaceuticalsNULLCompleted18 Years68 YearsBoth65Phase 2United States
3NCT00447980
(ClinicalTrials.gov)
January 20079/3/2007A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis PigmentosaA Phase II/III Study of Encapsulated Human NTC-201 Cell Implants Releasing Ciliary Neurotrophic Factor (CNTF) for Participants With Retinitis Pigmentosa Using Visual Field Sensitivity as the Primary OutcomeRetinitis PigmentosaDrug: NT-501Neurotech PharmaceuticalsNULLCompleted18 Years64 YearsBoth68Phase 2United States
4NCT00063765
(ClinicalTrials.gov)
June 20033/7/2003Evaluation of Safety of Ciliary Neurotrophic Factor Implants in the EyeA Phase I Study of NT-501-10 and NT-501-6A.02, Implants of Encapsulated Human NTC-210 Cells Releasing Ciliary Neurotrophic Factor (CNTF), in Patients With Retinitis PigmentosaRetinitis PigmentosaDrug: Ciliary Neurotrophic Factor Implant NT-501National Eye Institute (NEI)NULLCompletedN/AN/ABoth10Phase 1United States